Raymond James Financial
RYTM icon

Raymond James Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Raymond James Financial’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34M Buy
49,920
+8,805
+21% +$856K ﹤0.01% 2707
2025
Q4 		$4.4M Sell
41,115
-2,978
-7% -$316K ﹤0.01% 2623
2025
Q3 		$4.45M Buy
44,093
+33,547
+318% +$3.11M ﹤0.01% 2537
2025
Q2 		$666K Buy
+10,546
New +$646K ﹤0.01% 3829
2025
Q1 		– Sell
-3,892
Closed -$218K – 4932
2024
Q4 		$218K Buy
+3,892
New +$215K ﹤0.01% 4363

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Raymond James Financial's RYTM Position: Q1 2026 in Review

Raymond James Financial increased its Rhythm Pharmaceuticals (RYTM) stake by 21% in Q1 2026, buying an estimated $856K and bringing the position to 49,920 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Raymond James Financial first reported a position in RYTM in Q4 2024 and has held it in 5 quarters since. The position peaked at $4.45M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Raymond James Financial held 49,920 shares of Rhythm Pharmaceuticals worth $4.34M as of Q1 2026.
  • Raymond James Financial bought 8,805 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $856K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2707 holding.
  • Raymond James Financial first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Raymond James Financial's Rhythm Pharmaceuticals position peaked at $4.45M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.